SignalRx Pharmaceuticals, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.signalrx.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)β’ Click on a phase to view related trials
Phase 1
1 (100.0%)Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Phase 1
Terminated
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- SignalRX Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03059147
- Locations
- πΊπΈ
UC San Diego Moores Cancer Center, La Jolla, California, United States
News
No news found